Embracing Automation And Addressing The Barriers To Adoption
Source: bio-techne
While we’ve certainly come a long way, the ethos of technology and medicine remain — how can we do better? In this segment from the Cell & Gene Live event Considerations For Investing In Your Gene Therapy’s Automation Framework, TJ Cradick, Ph.D., CSO of Excision BioTherapeutics, and Matt Humes, head of lab automation at Beam Therapeutics, discuss current technological limitations and the barriers to industry-wide adoption.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
bio-techne
This website uses cookies to ensure you get the best experience on our website. Learn more